As most colorectal cancers (CRC) originate from precancerous adenomas, the ability to detect these lesions early remains central to reducing disease burden. A new review highlights the growing promise of blood-based biomarkers as a noninvasive alternative to conventional screening methods like colonoscopy—which, despite clinical effectiveness, continue to face compliance challenges due to their invasive nature.
Advances in multiomics—including proteomics, metabolomics, transcriptomics, and epigenomics—are enabling the identification of circulating biomarkers such as noncoding RNAs, DNA methylation signatures, disease-specific proteins, and metabolic profiles from plasma and serum samples. Emerging technologies like liquid biopsy, extracellular vesicle profiling, and machine learning–driven analytics are further enhancing the sensitivity and specificity of early adenoma detection.